Associated tags: TSX, Patient, Pharmaceutical industry, Methotrexate, Hematopoietic stem cell transplantation, Hematology, Customer service, Blood, Treosulfan, Rheumatoid arthritis, Allergy, Health Canada, FDA, Collaboration, World Health Organization, Glioma
Specifically, we achieved organic year-over-year revenue growth of 27% and IXINITY contributed an additional $9.5 million for the fourth quarter of 2020.
Key Points:
- Specifically, we achieved organic year-over-year revenue growth of 27% and IXINITY contributed an additional $9.5 million for the fourth quarter of 2020.
- Approximately 85% of IXINITY revenue for the quarter accrued to Medexus in March and as such, was highly accretive.
- For the fiscal year ended March 31, 2020, total revenue was $74.4 million compared to revenue of $33.9 million for the fiscal year ended March 31, 2019.
- Adjusted EBITDA* for the year-ended March 31, 2020 was $6.0 million compared to $2.4 million for the fiscal year ended March 31, 2019.
MONTREAL, June 17, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, June 23, 2020 to discuss the Companys financial results for the fiscal year-ended March 31, 2020, as well as the Companys corporate progress and other developments.
Key Points:
- MONTREAL, June 17, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, June 23, 2020 to discuss the Companys financial results for the fiscal year-ended March 31, 2020, as well as the Companys corporate progress and other developments.
- The Company expects to file its financial statements along with its MD&A post market on June 22, 2020.
- A webcast replay will be available on the Companys Investor Events section of the website ( www.medexus.com/news-events ) through September 23, 2020.
- Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology and allergy.
This press release contains forward-looking information within the meaning of applicable securities legislation.
Key Points:
- This press release contains forward-looking information within the meaning of applicable securities legislation.
- Forward-looking information includes, but is not limited to, statements with respect to future business operation, including with respect to the expected growth of the Companys pharmaceutical portfolio and pipeline.
- All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements.
- Since forward-looking information addresses future events and conditions, by its very nature they involve inherent risks and uncertainties.
Aggregate preliminary unaudited sales estimates for IXINITY during Q4 2020 totaled U.S. $8.3 million, which represents an 18.5% year over year increase.
Key Points:
- Aggregate preliminary unaudited sales estimates for IXINITY during Q4 2020 totaled U.S. $8.3 million, which represents an 18.5% year over year increase.
- Approximately 85% of those IXINITY sales accrued to the benefit of Medexus post-Acquisition and as such, the addition of IXINITY was highly accretive to Medexus for the quarter.
- Mr. Adelman joined Medexus from Aptevo immediately following the completion of the Acquisition.
- Peter van der Velden, Chairman of the Board of Medexus commented, Medexus business remains strong and is well positioned to emerge even stronger as the economy re-opens.
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements).
Key Points:
- Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements).
- The words anticipates, believes, expects, will, plans and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
- In addition, liquidity and volatility, credit availability and market and financial conditions generally could change at any time as a result.
- Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
MONTREAL, April 08, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the pan-Canadian Pharmaceutical Alliance (pCPA) price negotiations for Triamcinolone Hexacetonide Injectable Suspension 20mg/mL (TH)in Canada are completed with expected public reimbursement to roll out in the respective provinces over the coming months.
Key Points:
- MONTREAL, April 08, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the pan-Canadian Pharmaceutical Alliance (pCPA) price negotiations for Triamcinolone Hexacetonide Injectable Suspension 20mg/mL (TH)in Canada are completed with expected public reimbursement to roll out in the respective provinces over the coming months.
- As previously reported, there has been a long-standing drug shortage of Triamcinolone Hexacetonide in Canada.
- Ken dEntremont, Chief Executive Officer of Medexus, commented, Public reimbursement marks an important milestone for the Company, as it dramatically increases the sales potential and market access to our TH product.
- Public reimbursement for TH is particularly important in the current COVID-19 healthcare environment where patient visits to hospitals should be reduced and focused on urgent patient needs.
This press release contains forward-looking information within the meaning of applicable securities legislation.
Key Points:
- This press release contains forward-looking information within the meaning of applicable securities legislation.
- Forward-looking information includes, but is not limited to, statements with respect to future business operation, including with respect to the expected growth of the Companys pharmaceutical portfolio and pipeline.
- All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements.
- Since forward-looking information addresses future events and conditions, by its very nature they involve inherent risks and uncertainties.
The World Health Organization has declared COVID-19 a pandemic and, as the crisis deepens in North America, Medexus is actively assessing and responding where possible to its potential impact on the Companys business.
Key Points:
- The World Health Organization has declared COVID-19 a pandemic and, as the crisis deepens in North America, Medexus is actively assessing and responding where possible to its potential impact on the Companys business.
- The welfare and safety of Medexus personnel and the individuals with which the business interacts is a key priority for the Company.
- Medexus has taken prudent steps in accordance with its business continuity procedures to help reduce the spread of the virus and to support and protect the health of its employees, partners and customers.
- Ken dEntremont further commented: We continue to conduct business as usual to the extent possible despite the global situation.
Retrieved on:
Friday, February 28, 2020
IXINITY is an FDA approved product with strong brand equity and a track record of safety, efficacy and growing sales.
Key Points:
- IXINITY is an FDA approved product with strong brand equity and a track record of safety, efficacy and growing sales.
- The terms and conditions of the Acquisition are governed by a purchase agreement entered into between Medexus US and the Vendor (the Purchase Agreement).
- Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform.
- Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics.
Retrieved on:
Tuesday, February 18, 2020
Ken dEntremont, Chief Executive Officer of Medexus, commented, We achieved revenue of $16.2 million for the three months ended December 31, 2019, compared to $14.4 million for the same period last year.
Key Points:
- Ken dEntremont, Chief Executive Officer of Medexus, commented, We achieved revenue of $16.2 million for the three months ended December 31, 2019, compared to $14.4 million for the same period last year.
- Mr. dEntremont continued, During the third quarter, we launched new Metoject Subcutaneous doses of 10mg/0.2ml and 12.5mg/0.25ml.
- For the three months ended December 31, 2019, total revenues were $16.2 million, compared to revenue of $14.4 million for the three months ended December 31, 2018.
- Adjusted EBITDA** was $0.7 million for the three-month period ended December 31, 2019 compared to $2.2 million for the same period last year.
